Bodytechmed Signs Local Production Agreement for Point-of-Care Diagnostic Products with Florida, USA

Choi Eui-yeol, CEO of Boditech Med (left), and Billamil Florida Enterprise Senior Vice President signed an agreement for the local production of Boditech Med's point-of-care diagnostic products.

[Asia Economy Reporter Lee Gwanju] Boditech Med has signed an agreement with the state of Florida, USA, to locally produce point-of-care diagnostic products and is making a full-scale entry into the North American in vitro diagnostics market.

On the 18th, Boditech Med announced that it had signed a Memorandum of Understanding (MOU) with the state of Florida to ensure the stable supply of Boditech Med's various point-of-care diagnostic products.

Through this agreement, both parties plan to cooperate to ensure the smooth supply of point-of-care diagnostic products related to cardiovascular, cancer, hormone, and infectious diseases throughout the United States, including Florida. Boditech Med plans to establish a corporation in Florida for the local production of its various point-of-care diagnostic products and build production facilities, and will mutually cooperate with Florida on various supports.

Boditech Med has secured a stable supply chain within the United States for its COVID-19 rapid antigen self-test kit, which is currently undergoing FDA Emergency Use Authorization (EUA).

Choi Eui-yeol, CEO of Boditech Med, said, “The North American region is experiencing continuous growth in the in vitro diagnostics market due to increasing demand for diagnosis of various infectious diseases and early diagnosis of cardiovascular diseases. We will make a full-scale entry into the North American in vitro diagnostics market through the MOU with Florida and become a game changer in the diagnostic industry in North America.”

This content was produced with the assistance of AI translation services.